SCHEMBL16123471

SCHEMBL16123471

O=C(O)CCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCC[C@H]1SC[C@H]2NC(=O)N[C@H]21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.68
▸ PKM P14618 3/20 0.68
▸ MEN1 O00255 1/20 0.68
▸ ABL1 P00519 1/20 0.68
▸ LMNA P02545 1/20 0.68
▸ IDE P14735 1/20 0.68
▸ MAPK1 P28482 1/20 0.68
▸ KMT2A Q03164 1/20 0.68
▸ RIN1 Q13671 1/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.68
▸ FOLH1 Q04609 6/20 0.68
▸ F2 P00734 1/20 0.62
▸ PRSS1 P07477 1/20 0.62
▸ PRSS2 P07478 1/20 0.62
▸ PRSS3 P35030 1/20 0.62
▸ TPSAB1 Q15661 1/20 0.62
▸ PLCD1 P51178 1/20 0.56
▸ CA12 O43570 1/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1300276 1.00 TDP1 (0.68) TDP1PKMMEN1ABL1LMNA
SCHEMBL23334534 1.00 TDP1 (0.68) TDP1PKMMEN1ABL1LMNA
SCHEMBL22769273 0.97 FOLH1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL30504309 0.96 FOLH1 (0.70) TDP1PKMMEN1ABL1LMNA
SCHEMBL13185305 0.94 FOLH1 (0.63) TDP1PKMMEN1ABL1LMNA
SCHEMBL18957487 0.93 TDP1 (0.66) TDP1PKMMEN1ABL1LMNA
SCHEMBL8131388 0.93 FOLH1 (0.71) TDP1PKMMEN1ABL1LMNA
SCHEMBL26902897 0.92 TDP1 (0.62) TDP1PKMMEN1ABL1LMNA
SCHEMBL14795037 0.92 TDP1 (0.62) TDP1PKMMEN1ABL1LMNA
SCHEMBL13791515 0.91 FOLH1 (0.62) TDP1PKMMEN1ABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-05-09 — — US disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
WO-2014149164-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 TDP1 3334/4885PKM 586/4885MEN1 2025/4885
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 TDP1 3334/4885PKM 586/4885MEN1 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback